Details for New Drug Application (NDA): 216229
✉ Email this page to a colleague
The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 216229
Tradename: | DEFERASIROX |
Applicant: | Annora Pharma |
Ingredient: | deferasirox |
Patents: | 0 |
Suppliers and Packaging for NDA: 216229
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DEFERASIROX | deferasirox | GRANULE;ORAL | 216229 | ANDA | Camber Pharmaceuticals, Inc. | 31722-029 | 31722-029-32 | 30 PACKET in 1 CARTON (31722-029-32) / 1 GRANULE in 1 PACKET |
DEFERASIROX | deferasirox | GRANULE;ORAL | 216229 | ANDA | Camber Pharmaceuticals, Inc. | 31722-030 | 31722-030-32 | 30 PACKET in 1 CARTON (31722-030-32) / 1 GRANULE in 1 PACKET |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 180MG | ||||
Approval Date: | Sep 22, 2022 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 360MG | ||||
Approval Date: | Sep 22, 2022 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 90MG | ||||
Approval Date: | Mar 16, 2023 | TE: | AB | RLD: | No |
Complete Access Available with Subscription